Acurx Pharmaceuticals, Inc. announces pricing of $15 Million underwritten Initial public offering of common stock Jun 25, 2021
Acurx Announces Positive Phase 2A Clinical Trial Results for Ibezapolstat in C. difficile Infection at Prominent International Conference Nov 19, 2020
Acurx Announces All Patients Demonstrated Clinical and Sustained Cure in Ph2A Open-Label Trial of Ibezapolstat for Treatment of C. difficile Infection (CDI) Nov 5, 2020
Acurx Actively Enrolling Patients in Ph2 Clinical Trial of its Lead Antibiotic for Treatment of Clostridioides difficile Infection (CDI) Jul 23, 2020
Acurx Receives USAN Approval of Non-proprietary Name Ibezapolstat for Its Phase 2 Novel, First-in-Class Antibiotic for C. difficile Infection Jan 15, 2020
Acurx's Novel Lead Antibiotic Candidate Presented at Two Prominent International Scientific Conferences Oct 3, 2019
Acurx Receives FDA Fast Track Designation for ACX-362E for the Treatment of C. difficile infection Jan 16, 2019
